Answers are grounded in this paper and cite their sources.
< 0.0051). These results suggest that further evidence is needed to support the clinical adoption of pharmacogenomics in non-cancer therapeutic areas.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: